Ignite Creation Date:
2024-05-06 @ 8:53 AM
Last Modification Date:
2024-10-26 @ 12:06 PM
Study NCT ID:
NCT02840058
Status:
UNKNOWN
Last Update Posted:
2021-08-02
First Post:
2016-07-13
Brief Title:
Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 PDL1
Sponsor:
Centre Hospitalier Universitaire de Besancon
Organization:
Centre Hospitalier Universitaire de Besancon
Study Overview
Official Title:
Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 PDL1
Status:
UNKNOWN
Status Verified Date:
2021-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ITHER
Brief Summary:
Recent scientific advances have shown the important role of immune system against cancer Today many immunological biotherapy like anti-PD1PDL-1 are available in cancer treatment and generate durable clinical responses in some patients The development of tools for monitoring anti-tumor immune responses dynamically is a major challenge to predict the effectiveness of immunotherapies anti-PD-1 and anti-PDL-1
Thus the objective of our study is to analyse the interest of the monitoring of anti-telomerase T helper 1 TH1 responses in predicting the efficacy of immunotherapy using an immunoassay developed by our group
Thus the objective of our study is to analyse the interest of the monitoring of anti-telomerase T helper 1 TH1 responses in predicting the efficacy of immunotherapy using an immunoassay developed by our group
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None